Spesolimab.  Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases

Valdemar Wendelboe Nielsen; Yiqiu Yao; Alexander Egeberg; Simon Francis Thomsen

doi:10.1358/dof.2023.48.3.3500035

Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases

Valdemar Wendelboe Nielsen^*, Yiqiu Yao, Alexander Egeberg, Simon Francis Thomsen

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

The palette of biologic therapy is growing rapidly to improve the treatment and management of inflammatory immune-driven diseases. The interleukin-36 (IL-36) receptor has become a prom-ising target for therapeutic intervention, with early studies of anti-IL-36 receptor treatment demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symp-toms. Spesolimab, a humanized anti-IL-36 receptor monoclo-nal antibody, is one of the latest additions, showing promising results in the treatment of generalized pustular psoriasis and a possible effect in ulcerative colitis. In this review, we present the current literature on spesolimab, including pharmacodynam-ics, pharmacokinetics, efficacy and safety in the treatment of several immune-mediated inflammatory diseases.

Original language	English
Journal	Drugs of the Future
Volume	48
Issue number	3
Pages (from-to)	165-172
ISSN	0377-8282
DOIs	https://doi.org/10.1358/dof.2023.48.3.3500035
Publication status	Published - 2023

Keywords

Spesolimab
BI-655130
MAB-92
Generalized pustular psoriasis
IL-36R
Monoclonal antibody

Access to Document

10.1358/dof.2023.48.3.3500035

Cite this

@article{6409744808624ac9bafcff0ccf0d226c,

title = "Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases",

abstract = "The palette of biologic therapy is growing rapidly to improve the treatment and management of inflammatory immune-driven diseases. The interleukin-36 (IL-36) receptor has become a prom-ising target for therapeutic intervention, with early studies of anti-IL-36 receptor treatment demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symp-toms. Spesolimab, a humanized anti-IL-36 receptor monoclo-nal antibody, is one of the latest additions, showing promising results in the treatment of generalized pustular psoriasis and a possible effect in ulcerative colitis. In this review, we present the current literature on spesolimab, including pharmacodynam-ics, pharmacokinetics, efficacy and safety in the treatment of several immune-mediated inflammatory diseases.",

keywords = "Spesolimab, BI-655130, MAB-92, Generalized pustular psoriasis, IL-36R, Monoclonal antibody",

author = "Nielsen, {Valdemar Wendelboe} and Yiqiu Yao and Alexander Egeberg and Thomsen, {Simon Francis}",

year = "2023",

doi = "10.1358/dof.2023.48.3.3500035",

language = "English",

volume = "48",

pages = "165--172",

journal = "Drugs of the Future",

issn = "0377-8282",

publisher = "Prous Science",

number = "3",

}

TY - JOUR

T1 - Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases

AU - Nielsen, Valdemar Wendelboe

AU - Yao, Yiqiu

AU - Egeberg, Alexander

AU - Thomsen, Simon Francis

PY - 2023

Y1 - 2023

N2 - The palette of biologic therapy is growing rapidly to improve the treatment and management of inflammatory immune-driven diseases. The interleukin-36 (IL-36) receptor has become a prom-ising target for therapeutic intervention, with early studies of anti-IL-36 receptor treatment demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symp-toms. Spesolimab, a humanized anti-IL-36 receptor monoclo-nal antibody, is one of the latest additions, showing promising results in the treatment of generalized pustular psoriasis and a possible effect in ulcerative colitis. In this review, we present the current literature on spesolimab, including pharmacodynam-ics, pharmacokinetics, efficacy and safety in the treatment of several immune-mediated inflammatory diseases.

AB - The palette of biologic therapy is growing rapidly to improve the treatment and management of inflammatory immune-driven diseases. The interleukin-36 (IL-36) receptor has become a prom-ising target for therapeutic intervention, with early studies of anti-IL-36 receptor treatment demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symp-toms. Spesolimab, a humanized anti-IL-36 receptor monoclo-nal antibody, is one of the latest additions, showing promising results in the treatment of generalized pustular psoriasis and a possible effect in ulcerative colitis. In this review, we present the current literature on spesolimab, including pharmacodynam-ics, pharmacokinetics, efficacy and safety in the treatment of several immune-mediated inflammatory diseases.

KW - Spesolimab

KW - BI-655130

KW - MAB-92

KW - Generalized pustular psoriasis

KW - IL-36R

KW - Monoclonal antibody

U2 - 10.1358/dof.2023.48.3.3500035

DO - 10.1358/dof.2023.48.3.3500035

M3 - Journal article

SN - 0377-8282

VL - 48

SP - 165

EP - 172

JO - Drugs of the Future

JF - Drugs of the Future

IS - 3

ER -